Table 2.
Baseline characteristics of the continuously monitored participants (N=171).
|
|
Characteristics | Total | |
| Demographics |
|
||
|
|
Age (years), mean (SD) | 53.23 (13.58) | |
|
|
Female, n (%) | 85 (50) | |
| Medical history | |||
|
|
Heart failure, n (%) | 1 (1) | |
|
|
Hypertension, n (%) | 47 (28) | |
|
|
Diabetes mellitus, n (%) | 23 (14) | |
|
|
Previous stroke/SEa/TIAb, n (%) | 4 (2) | |
|
|
Coronary artery disease, n (%) | 14 (8) | |
|
|
Vascular disease, n (%) | 8 (5) | |
|
|
Renal dysfunction, n (%) | 2 (1) | |
|
|
Bleeding history or predisposition, n (%) | 4 (2) | |
|
|
Sleep apnea, n (%) | 8 (5) | |
|
|
Hyperthyroidism, n (%) | 1 (1) | |
|
|
Current smoking, n (%) | 24 (14) | |
|
|
Current drinking, n (%) | 32 (19) | |
|
|
CHA2DS2-VAScc score, median (IQRd) | 1 (0.75-2.00) | |
|
|
HAS-BLEDe score, median (IQR) | 0 (0.00-1.00) | |
| Medications, n (%) |
|
||
|
|
Oral anticoagulant | 19 (11) | |
|
|
Antiplatelet drug | 11 (6) | |
|
|
Calcium channel blockers | 3 (2) | |
|
|
ACEI/ARBf | 10 (6) | |
|
|
Diuretic | 4 (2) | |
|
|
Digoxin | 1 (1) | |
| Antiarrhythmic drugs, n (%) | |||
|
|
Class I | 3 (2) | |
|
|
Betablocker | 3 (2) | |
|
|
Class III | 5 (3) | |
|
|
Class IV | 3 (2) | |
aSE: systemic arterial embolism.
bTIA: transient ischemic attack.
cCHA2DS2-VASc: congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, stroke (doubled), vascular disease, age 65-74 years, female sex.
dIQR: interquartile range.
eHAS-BLED: hypertension, abnormal renal function, abnormal liver function, stroke, bleeding, labile international normalized ratio, age>65 years, drugs or alcohol.
fACEI/ARB: angiotensin-converting-enzyme inhibitor, angiotensin receptor blockers.